Bavarian Nordic Comes Up On The Rails In RSV Race
Phase III Readout In Mid-2023
Executive Summary
GSK and Pfizer are both likely to get FDA approval for their respiratory syncytial virus products shortly but Bavarian Nordic is progressing well with its differentiated five RSV-specific antigen jab.